Shamburg News · 8-K filed Nov 5, 2026, 8:35 AM EST

Aptevo Reports Substantial Reduction in Infusion-Related Reactions with Mipletamig in Frontline AML

APVO · Aptevo Therapeutics Inc.

  • Other event
  • Materiality: medium

On November 5, 2026, Aptevo Therapeutics Inc. announced that successive refinements to the priming-dose regimen of its lead candidate mipletamig substantially reduced infusion-related reactions in the ongoing RAINIER study in frontline AML. The company said the data will be presented at the ASH 68th Annual Meeting from December 12-15, 2026, and that it expects to complete the current study by year-end 2026 and initiate Phase 2 development in 2027. The press release contains no quantified reduction rate or efficacy data.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-448714.

Written from the filing by Shamburg Markets. Figures are as reported by the company.